Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Amanda Z VelezDepartment of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC 27559.
Jana N RadinDepartment of Microbiology and Immunology, University of Iowa, Iowa City, IA 52242.
Emily N KennedyDepartment of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC 27559.ORCID 0000-0002-5668-4339
Joshua B ParsonsDivision of Infectious Diseases, Duke University School of Medicine, Durham, NC 27710.ORCID 0000-0002-0589-3587
Heather M TongDepartment of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC 27559.
Emma JungDepartment of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC 27559.
Emily AlamDepartment of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC 27559.
Lauren C RadlinskiDepartment of Medical Microbiology and Immunology, School of Medicine, University of California, Davis, CA 95616.
Nikki J WagnerDepartment of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC 27559.ORCID 0000-0002-4872-3107
Vance G FowlerDivision of Infectious Diseases, Duke University School of Medicine, Durham, NC 27710.ORCID 0000-0002-8048-0897
Sarah E RoweDepartment of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC 27559.ORCID 0000-0001-8955-359X
Thomas Kehl-FieDepartment of Microbiology and Immunology, University of Iowa, Iowa City, IA 52242.ORCID 0000-0001-8234-1113
Brian P ConlonDepartment of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC 27559.ORCID 0000-0002-2155-8375
Funding
Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
Diabetes and Antibiotic Treatment FailureR01AI173004 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Brian Patrick Conlon, Lance R. Thurlow · 2023 to 2026
$2.8M
Calprotectin and Antibiotic Activities at the Infection InterfaceR01AI179695 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Brian Patrick Conlon, Thomas Everett Kehl-Fie · 2024 to 2026
$2.3M
Identifying the contribution of zinc limitation to antibiotic tolerance during S. aureus infectionR21AI159369 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CONLON, BRIAN PATRICK · 2021 to 2022
$431k
Zeiss LSM900 laser scanning confocal microscope for the University of North Carolina at Chapel HillS10OD036215 · OD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ARIEL, PABLO · 2024 to 2024
$262k
Identifying the role of manganese limitation in antibiotic killing of Staphylococcus aureusF30AI169746 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Amanda Zoyla Velez · 2023 to 2026
$183k
HHS | NIH | NIAID | Division of Microbiology and Infectious Diseases (DMID) F30AI169746HHS | NIH | NIAID | Division of Microbiology and Infectious Diseases (DMID) R01AI173004HHS | NIH | NIAID | Division of Microbiology and Infectious Diseases (DMID) R01AI179695HHS | NIH | NIAID | Division of Microbiology and Infectious Diseases (DMID) R21AI159369NCI NIH HHS P30 CA016086NIAID NIH HHS F30 AI169746NIAID NIH HHS R01 AI173004NIAID NIH HHS R01 AI179695NIAID NIH HHS R21 AI159369NIH HHS S10 OD036215
6 · The paper itself
Abstract
β-lactam antibiotics are among the most widely used treatments for bacterial infections, yet therapeutic failure is common even when no genetic resistance is detected. Understanding how host factors influence antibiotic efficacy is critical for improving outcomes. Here, we identify a host-derived mechanism of antibiotic tolerance mediated by calprotectin (CP), a zinc-binding protein released in large quantities by neutrophils during infection. We show that CP induces tolerance to β-lactam antibiotics in
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The innate immune protein calprotectin ablates the bactericidal activity of β-lactam antibiotics. · full record | OpenQuestion